

February 17, 2025

**Additional Approval of Dosage Form of CANALIA® Combination OD Tablets,  
Selective DPP-4 inhibitor/SGLT2 inhibitor Combination Drug  
~ First OD Tablets of Selective DPP-4 inhibitor/SGLT2 inhibitor Combination Drug  
in Japan ~**

Mitsubishi Tanabe Pharma Corporation (Head Office: Chuo-ku, Osaka; Representative Director: Akihiro Tsujimura; hereinafter, "MTPC"), a member of the Mitsubishi Chemical Group, obtained approval for an additional dosage form of CANALIA® Combination OD Tablets, which is orally disintegrating tablets (OD tablets) for CANALIA® Combination Tablets, the combination drug of selective DPP-4 inhibitor and SGLT2 inhibitor on February 17, 2025.

CANALIA® Combination OD Tablets is the first OD tablets of selective DPP-4 inhibitor and SGLT2 inhibitor combination drug approved in Japan. Since it disintegrates easily in a small amount of water, it dissolves quickly with saliva in the mouth and is easy to swallow and can be taken without or with water without depending on the place. It is expected to improve convenience and to continue taking the drug for people with type 2 diabetes who need continuous treatment.

Use of CANALIA® Combination OD Tablets by patients with type 2 diabetes mellitus whose blood glucose levels are stably controlled by concomitant treatment with selective DPP-4 inhibitor TENELIA® Tablets/OD Tablets (hereinafter, "TENELIA®") and SGLT2 inhibitor CANAGLU® Tablets/OD Tablets (hereinafter, "CANAGLU®") will reduce the number of medicine and improve medication adherence. Use of CANALIA® Combination OD Tablets by type 2 diabetes mellitus patients who have inadequate glycemic control to monotherapy with TENELIA® or CANAGLU® is also expected to result in improved blood glucose control.

MTPC will continue working to deliver the new treatment options for people living with type 2 diabetes to enhance satisfaction with treatment and convenience.

*Contact:*

Mitsubishi Tanabe Pharma Corporation  
Pharma Business Strategy Division  
PR Department  
+81-6-6205-5119